RBC Capital raised the firm’s price target on MannKind (MNKD) to $7 from $5 and keeps a Sector Perform rating on the shares. The company reported another strong quarter with total revenues up 37%, continued pull-through of Tyvaso DPI royalty and collaboration revenues, and appreciable Afrezza performance, supporting the topline, the analyst tells investors in a research note.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter